Multihance (Gadobenate Dimeglumine)

Gadobenate dimeglumine, the active ingredient in Multihance, is a gadolinium-based contrast agent presented as an injection solution for intravenous use. It enhances magnetic resonance imaging and is used in diagnostic imaging of various organ systems.

GNH USA supplies Multihance as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Multihance is used as a gadolinium‑based contrast agent for magnetic resonance imaging of several organ systems.

- Central nervous system: improves lesion detection and delineation on T1‑weighted MRI. - Liver: enhances visualization of focal hepatic lesions and vascular structures. - Cardiovascular system: provides high‑contrast images of cardiac chambers, vessels, and myocardial perfusion. - Musculoskeletal system: clarifies soft‑tissue and joint pathology on MRI.

Multihance may cause a range of adverse reactions following intravenous administration.

Common Side Effects: - Nausea: mild to moderate feeling of queasiness. - Headache: transient headache during or after injection. - Injection site discomfort: warmth or pain at the site of administration. - Dizziness: brief episodes of light‑headedness. - Mild hypertension: temporary rise in blood pressure.

Serious or Rare Side Effects: - Anaphylactic reaction: severe allergic response requiring immediate medical attention. - Nephrogenic systemic fibrosis (NSF): rare fibrotic disorder in patients with severe renal impairment. - Severe hypotension: marked drop in blood pressure. - Cardiac arrest: extremely rare but life‑threatening event. - Acute kidney injury: sudden deterioration of renal function.

Before using Multihance, clinicians should consider several safety measures.

- Renal function assessment: evaluate glomerular filtration rate prior to administration. - History of allergic reactions: screen for prior hypersensitivity to contrast media. - Pregnancy: use only if clearly needed; safety data are limited. - Concurrent nephrotoxic drugs: avoid or closely monitor renal function when combined with agents such as aminoglycosides or NSAIDs. - Gadolinium retention: consider cumulative exposure in patients requiring multiple contrast studies. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Multihance may interact with other medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Renal‑impairment agents: avoid concurrent high‑dose iodinated contrast agents. - Nephrotoxic drugs: avoid simultaneous use of aminoglycosides, NSAIDs, or other renal‑toxic medications. - Chelating agents: avoid co‑administration of deferoxamine or similar agents.

Moderate Interactions (Monitor Closely): - Beta‑blockers: monitor hemodynamic response during and after injection. - Diuretics: observe fluid balance and renal function. - Other MRI contrast agents: stagger dosing to reduce cumulative gadolinium load.